Cancer drug imatinib tested for rare eye melanoma – but trial stops early
NCT ID NCT00421317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclear if imatinib helps patients with this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imatinib
What this could lead to
If it works, this could point toward a treatment option for metastatic ocular melanoma, a rare and hard-to-treat cancer.
What could go wrong
This trial was terminated early and enrolled only 13 people, so results are very limited. Imatinib may not shrink tumors or improve survival, and it can cause side effects like fatigue, nausea, and liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Francois Baclesse
Caen, 14076, France
-
Centre Georges-Francois Leclerc
Dijon, 21079, France
-
Centre Gustave Roussy
Villejuif, 94805, France
-
Centre Hospitalier Regional Universitaire
Lille, 59035, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Paul Strauss
Strasbourg, 67065, France
-
Centre Val d'Aurelle Paul Lamarque
Montpellier, 34298, France
-
Hopital Universitaire de Hautepierre
Strasbourg, 67098, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Curie
Paris, 75248, France